

Date: 13 August 2021

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex,
Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Outcome of Board Meeting held on 13 August 2021

Ref: Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,


With reference to the above subject, and pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that in the meeting of the Board of Directors of the Company held today i.e., Friday, 13 August 2021, the Board of Directors of the Company inter alia discussed, considered and approved the following:

- Un-audited financial results (both standalone and consolidated) for the quarter ended 30 June 2021
- Limited Review Report thereon as on 30 June 2021

The meeting commenced at 3.15 PM and concluded at 6.30 PM.
This is for your information and records

Yours truly,

For Banka BioLoo Limited



Sri Bala Aditya Yanamandra
Company Secretary & Compliance Officer

Date: 13 August 2021

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Submission of un-audited financial results (both standalone and consolidated) for the quarter ended 30 June 2021, along with Limited Review Report thereon as on that date

Dear Sir/Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable circular(s), we herewith enclose the following:

- Un-audited financial results (both standalone and consolidated) for the quarter ended 30 June 2021
- Limited Review Report thereon as on 30 June 2021

The aforesaid financial results and statements are duly approved and recommended by the Audit Committee in their meeting held on 13 August 2021.

These are also being made available on the website of the Company at www.bankabio.com

Kindly take the same on record.

Thank you,

For Banka BioLoo Limited



Sri Bala Aditya Yanamandra
Company Secretary & Compliance Officer

Encls as above



Independent Auditor's Review Report on the Quarterly Unaudited Standalone and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To The Board of Directors of
BANKA BIOLOO LIMITED**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of **BANKA BIOLOO LIMITED** for the quarter ended June 30, 2021 (the "statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2020 ('the Circular').
2. This Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, except for the effects/possible effects of qualifications as described in the previous paragraph, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.
5. We draw your attention that the statement which indicates the preparation of financial results of the Company on going concern basis for reasons stated therein. The appropriateness of assumption of going concern is dependent upon revival of market and consequently the Company's ability to generate sustainable cash flows in future to meet its obligations.



Our report is not modified in respect of this matter.

For PRSV & Co.LLP
Chartered Accountants
Firm Registration No: S200016


Y. Venkateswarlu
Partner
Membership No: 222068



Place: Hyderabad
Date: August 13, 2021

UDIN: 21222068AAAACL2485

BANKA BIOLOO LIMITED

Unaudited STANDALONE Statement of Financial Results for the quarter

ended 30 June 2021

(Rs. In Lakhs)

S. No	Particulars	Quarter ended			Year ended
		30.06.2021 Unaudited	31.03.2021 Audited	30.06.2020 Unaudited	31.03.2021 Audited
1	Income				
	Gross Revenue from operations	915.46	1,126.06	730.22	3,566.53
	Less: Duties & Taxes	(112.46)	(163.44)	(67.54)	(520.77)
	Revenue from Operations	803.00	962.61	662.68	3,045.76
	Other operating revenue	-	-	-	-
	Other income	12.05	30.34	6.60	57.61
	Total Income	815.05	992.96	669.28	3,103.37
2	Expenses				
	Cost of materials consumed	147.53	281.18	71.98	702.22
	Changes in inventories of finished goods & work-in-progress	(7.08)	(192.76)	(21.23)	(321.13)
	Employee benefits expense	349.22	392.34	401.64	1,302.45
	Finance costs	41.14	48.83	33.63	151.45
	Depreciation and amortisation expense	19.80	20.26	12.46	59.73
	Other expenses	207.86	431.56	75.83	1,021.65
	Total expenses	758.46	981.42	574.30	2,216.37
3	Profit/(loss) before tax	56.59	11.54	94.97	187.00
4	Tax expense				
	(1) Current tax	-	(33.70)	16.85	-
	(2) Taxes for earlier years	-	(19.29)	-	(19.29)
	(3) MAT Credit	-	-	-	-
	(4) Deferred tax	(8.61)	(6.41)	(4.21)	(14.36)
	Total Tax expense	-8.61	(59.39)	12.64	(33.64)
5	Profit after tax	65.20	70.93	82.34	220.64
	Other comprehensive income				
	<i>Items that will not be reclassified to profit and loss</i>				
	Remeasurement of post-employment benefit obligations	-	27.16	-	27.16
	Income tax effect on items that will not be reclassified to	-	(6.65)	-	(6.65)
	Other comprehensive income for the year	-	20.51	-	20.51
	Total comprehensive income for the year	65.20	91.44	82.34	241.15
6	Paid up equity share capital (Face value Rs. 10/- each)	1,028.11	1,028.11	1,028.11	1,028.11
7	Earnings per share				
	Basic and Diluted Earnings per share (in Rs.)	0.63	0.69	0.80	2.15
		(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

FOR & ON BEHALF OF BOARD OF DIRECTORS



Vishal Murarka

Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 13.08.2021

Notes:

1. The above unaudited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13 August 2021.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
4. The Standalone Financial Results for the quarter ended 30 June 2021 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31st March 2021.
5. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to manufacturing, supplying and installation of Bio toilets and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
6. During the financial year ended 31st March 2018, the company has completed its initial public Offer (IPO) of 10,98,000 Equity Shares of Rs:10/- each at a price of Rs.115 per share (including a premium of Rs.105 per share).
7. Proceeds from Initial Public Offer of Equity Shares have been utilized as under:

S. No	Particulars	Projected Utilization of Funds as per Prospectus	Actual Utilization of Funds till 30.06.2021	Deviation/ Variation (if any)
1	Long Term Working Capital Requirement	797.88	797.88	
2	General Corporate Purpose	231.62	231.62	
3	Issue Related Expenses-Company portion	61.10	61.08	
4	Capital expenditure at existing inoculum at Aler	75.21	75.21	
5	Capital expenditure at proposed new unit at Ibrahimpatnam	96.89	26.14	
	Total	1,262.70	1191.92	-

8. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets,
9. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For Banka BioLoo Limited



Vishal Murarka

Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 13 August 2021

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To The Board of Directors of
BANKA BIOLOO LIMITED**

1. We have reviewed the accompanying Statement of Consolidated unaudited financial results of **BANKA BIOLOO LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive loss of its joint ventures for the quarter ended June 30, 2021 (the "statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2021 dated March 29, 2019 ('the Circular').
2. This Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Parent's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes the results of the following entities.

Holding Company

BANKA BIOLOO LIMITED

Subsidiary

Banka Earth Foundation

Associates

- a) Sai Banka SPV Pvt Ltd
- b) Sustainable Sanitation Industry Association

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, except for the effects/possible effects of qualifications as described in the previous paragraph and based on the consideration of the review reports of other auditors referred to in paragraph 6,7 and 8 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.
6. The accompanying statement includes the unaudited interim financial results and other financial information of 1 wholly owned subsidiary and 2 associates whose unaudited interim financial results include total revenues of Rs. Nil and total net loss after tax of Rs. 61,414/- and total comprehensive income of Rs. Nil, for the quarter ended June 30, 2021 as considered in the consolidated unaudited financial results. These interim financial results and other financial information are unaudited and have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these wholly owned subsidiary and 2 associates are based solely on those unaudited financial statement/financial information furnished by the Management.



7. We draw your attention that the statement which indicates the preparation of financial results of the Company on going concern basis for reasons stated therein. The appropriateness of assumption of going concern is dependent upon revival of market and consequently the Company's ability to generate sustainable cash flows in future to meet its obligations. Our conclusion on the Statement is not modified in respect of the above matter.

For PRSV & Co.LLP

Chartered Accountants

Firm Registration No: S200016

Y.Venkateswarlu

Partner

Membership No: 222068



Place: Hyderabad

Date: August 13, 2021

UDIN: 21222068 AAAACM4960

BANKA BIOLOO LIMITED

Unaudited CONSOLIDATED Statement of Financial Results for the quarter ended 30 June 2021

(Rs. In Lakhs)

S. No	Particulars	Quarter ended			Year ended
		30.06.2021 Unaudited	31.03.2021 Audited	30.06.2020 Unaudited	31.03.2021 Audited
1	Income				
	Gross Revenue from operations	915.46	1,126.06	730.22	3,566.53
	Less:Duties & Taxes	(112.46)	(163.44)	(67.54)	(520.77)
	Revenue from Operations	803.00	962.61	662.68	3,045.76
	Other operating revenue	-	-	-	-
	Other income	12.05	30.36	6.61	57.62
	Total Income	815.05	992.97	669.29	3,103.38
2	Expenses				
	Cost of materials consumed	147.53	281.18	71.98	702.22
	Changes in inventories of finished goods & work- in-progress	(7.08)	(192.76)	(21.23)	(321.13)
	Employee benefits expense	349.22	392.34	401.64	1,302.45
	Finance costs	41.14	48.83	33.63	151.45
	Depreciation and amortisation expense	19.80	20.26	12.46	59.73
	Other expenses	207.86	431.56	75.83	1,021.65
	Total expenses	758.46	981.42	574.30	2,916.37
3	Share of profit/(loss) of Associates	(0.61)	(0.17)	-	(0.17)
4	Profit/(loss) before tax	55.97	11.38	94.98	186.84
5	Tax expense				
	(1) Current tax	-	(33.70)	16.85	-
	(2) Taxes for earlier years	-	(19.29)	-	(19.29)
	(3) MAT Credit	-	-	-	-
	(4) Deferred tax	(8.61)	(6.41)	(4.21)	(14.36)
	Total Tax expense	-8.61	(59.39)	12.64	(33.64)
6	Profit after tax	64.59	70.77	82.35	220.48
	Other comprehensive income				
	<i>Items that will not be reclassified to profit and loss</i>				
	Remeasurement of post-employment benefit obligations	-	27.16	-	27.16
	Income tax effect on items that will not be reclassified to	-	(6.65)	-	(6.65)
	Other comprehensive income for the year	-	20.51	-	20.51
	Total comprehensive income for the year	64.59	91.28	82.35	240.99
	Attributable to				
	Shareholders of the Company	64.59	91.28	82.35	240.99
	Non controlling interest	-	0.00	0.00	0.00
7	Paid up equity share capital (Face value Rs. 10/- each)	1,028.11	1,028.11	1,028.11	1,028.11
8	Earnings per share				
	Basic and Diluted Earnings per share (in Rs.)	0.63	0.89	0.80	2.34
		(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)



FOR & ON BEHALF OF BOARD OF DIRECTORS

 Vishal Murarka
 CEO & Executive Director
 DIN: 06729485


 Place: Hyderabad
 Date: 13.08.2021

Notes:

1. The above statement of Audited Consolidated Financial Results was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13 August 2021.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The consolidated financial results of the Group include the results of the Company and results of the following entities.

Name of the entity	Status
Banka Earth Foundation	Subsidiary
Sai Banka SPV Pvt Ltd	Associate
Sustainable Sanitation Industry Association	Associate

4. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
5. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets,
6. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.



For Banka BioLoo Limited

Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 13 August 2021

Date: 13 August 2021

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: Banka**Sub: Statement of deviation(s) or variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended 30 June 2021**

Dear Sir/Madam,

With reference to the above-cited subject, please find enclosed, herewith, the statement of deviation(s) or variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended 30 June 2021.

This is for your information and necessary records.

Thank you,

For Banka BioLoo Limited

Sri Bala Aditya Yanamandra
Company Secretary & Compliance Officer

STATEMENT OF DEVIATION(S) OR VARIATION(S)
[Under Regulation 32 (1) of SEBI (LODR) Regulations, 2015]

In reference to the compliance under regulation 32 (1) (a) & (b) of SEBI (LODR) Regulations, 2015, as required under Regulation 32 (8) of SEBI (LODR) Regulations, 2015, the Company, hereby, submits to the stock exchange, the statements of deviation(s) or variation(s) for the quarter ended on 30 June 2021.

a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;

We hereby inform you that there was no deviation in the utilisation of the proceeds of the public issue from the objects stated in the prospectus of the issue, as required under regulation 32 (1) (a) of SEBI (LODR) Regulations, 2015.

b) Indicating category-wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilisation of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilisation of funds;

We hereby inform that there has been no variation in the use of the proceeds from the objects stated in the prospectus dated 23 January 2018 or explanatory statement to the notice of the Extra-Ordinary General Meeting dated 16 November 2017, issued for Initial Public offering of securities, as per regulation 32 (1) (b) of SEBI (LODR) Regulations, 2015.

Thank you,

For Banka BioLoo Limited



Sri Bala Aditya Yanamandra
Company Secretary & Compliance Officer